Biomarkers will revolutionize the way we diagnose and treat Alzheimer‘s disease
Alzheimer‘s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible
Biomarkers in Alzheimer‘s disease: past, present and future
Biomarkers of oxidative damage and inflammation in Alzheimer‘s disease
Role of progranulin as a biomarker for Alzheimer‘s disease
Cerebrospinal fluid biomarkers of Alzheimer‘s disease
Blood-based biomarkers of Alzheimer‘s disease: challenging but feasible
Role of biochemical Alzheimer‘s disease biomarkers as end points in clinical trials
Biochemical markers in Alzheimer‘s disease clinical trials
Correlating familial Alzheimer‘s disease gene mutations with clinical phenotype
Tools to identify organ rejection and immune quiescence for biological understanding and personalized medical care
Rapid nanosensor device to detect biomarkers in whole blood
Survivors of childhood cancer have an increased risk of heart disease
Elafin: the first biomarker for graft-versus-host disease
Color-changing contact lenses indicate blood glucose level in diabetes
Hematocrit levels before and after PCI predict mortality outcome, study suggests
Identifying malignant breast cancer without an invasive biopsy
Cancer stem cells as a prognostic indicator for glioblastoma multiforme
Circulating endothelial progenitor cells as a surrogate marker for glioma prognosis and disease relapse
Glioblastoma microvesicles as an important mechanism of intercellular transportation and as a potential diagnostic biomarker
Conference Scene: Advancing toward personalized medicine
Biomarkers in systemic sclerosis
Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers
Current developments in salivary diagnostics
Acknowledgements